CD52 and prolymphocytic leukemia: High expression of CD52 provides an effective therapeutic approach for these patients with Campath (alemtuzumab), an anti-CD52 monoclonal antibody that has robust activity in newly diagnosed and recurrent T-PLL (5, 6).